Prognosis and duration

Time limited awards are recommended in early breast cancer and locally advanced breast cancer if needs are identified. In locally advanced breast cancer that does not respond to treatment needs are likely to persist, if needs are ongoing at renewal indefinite awards are recommended.

In recurrent or metastatic breast cancer indefinite awards are recommended if needs are identified.

Indefinite awards are also recommended for enduring side effects of treatment such as significant lymphoedema, enduring effects of chemotherapy and Radiation Induced Brachial Plexopathy – clear medical evidence of such effects should be available.

All information must be taken into account when considering the duration of disabling effects and the duration of disabling effects must be based on the particular circumstances of the individual claimant.

Amended May 2009